HIM
IMVT icon

Hillsdale Investment Management’s Immunovant IMVT Stock Holding History

Hillsdale Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,200
Closed -$3.24M – 632
2024
Q1 		$3.24M Buy
100,200
+8,200
+9% +$299K 0.26% 159
2023
Q4 		$3.88M Sell
92,000
-24,300
-21% -$894K 0.32% 120
2023
Q3 		$4.46M Sell
116,300
-21,800
-16% -$493K 0.41% 68
2023
Q2 		$2.62M Sell
138,100
-124,000
-47% -$2.31M 0.24% 151
2023
Q1 		$4.07M Buy
+262,100
New +$4.55M 0.35% 107

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Hillsdale Investment Management's IMVT Position: Q2 2024 in Review

Hillsdale Investment Management sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 100,200 shares — an estimated $3.24M sold.

Hillsdale Investment Management first reported a position in IMVT in Q1 2023 and held it in 5 quarters. The position peaked at $4.46M in Q3 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Hillsdale Investment Management reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 100,200 Immunovant shares in Q2 2024, an estimated $3.24M.
  • Hillsdale Investment Management first reported a position in Immunovant in Q1 2023 and held it in 5 quarters.
  • Hillsdale Investment Management's Immunovant position peaked at $4.46M in Q3 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Hillsdale Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.